{
    "clinical_study": {
        "@rank": "144447", 
        "arm_group": [
            {
                "arm_group_label": "BLI801 laxative - low dose", 
                "arm_group_type": "Experimental", 
                "description": "BLI801 laxative - oral solution"
            }, 
            {
                "arm_group_label": "BLI801 laxative - high dose", 
                "arm_group_type": "Experimental", 
                "description": "BLI801 laxative - oral solution"
            }
        ], 
        "brief_summary": {
            "textblock": "A pilot study to evaluate the safety and efficacy of multiple BLI801 doses in constipated\n      adults."
        }, 
        "brief_title": "A Safety and Efficacy Evaluation of BLI801 Laxative in Constipated Adults", 
        "condition": "Constipation", 
        "condition_browse": {
            "mesh_term": "Constipation"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Male or female subjects at least 18 years of age\n\n        Constipated, defined  by ROME definition:\n\n        Otherwise in good health, as determined by physical exam and medical history\n\n        Exclusion Criteria:\n\n        Subjects with known or suspected ileus, gastrointestinal obstruction, gastric retention,\n        bowel perforation, toxic colitis, toxic megacolon\n\n        Subjects taking laxatives  or prokinetic agents that refuse to discontinue these\n        treatments\n\n        Subjects who are allergic to any BLI801 component\n\n        Subjects currently taking narcotic analgesics or other medications known to cause\n        constipation\n\n        Subjects who, in the opinion of the Investigator, should not be included in the study for\n        any reason, including inability to follow study procedures\n\n        Subjects who have participated in an investigational clinical, surgical, drug, or device\n        study within the past 30 days\n\n        Subjects with an active history of drug or alcohol abuse"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 14, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01687985", 
            "org_study_id": "BLI801-202"
        }, 
        "intervention": [
            {
                "arm_group_label": "BLI801 laxative - low dose", 
                "description": "BLI801 laxative - oral solution", 
                "intervention_name": "BLI801 laxative - low dose", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BLI801 laxative - high dose", 
                "description": "BLI801 laxative - oral solution", 
                "intervention_name": "BLI801 laxative - high dose", 
                "intervention_type": "Drug", 
                "other_name": "BLI801"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Laxatives", 
                "Cathartics"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 2, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Anaheim", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92801"
                    }, 
                    "name": "Anaheim Clinical Trials"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brockton", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02302"
                    }, 
                    "name": "Commonwealth Clinical Studies"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chattanooga", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37421"
                    }, 
                    "name": "Clinsearch"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Germantown", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "38138"
                    }, 
                    "name": "Memphis Gastroenterology"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Safety and Efficacy Evaluation of BLI801 Laxative in Constipated Adults", 
        "overall_official": {
            "affiliation": "Braintree Laboratories, Inc.", 
            "last_name": "John McGowan, MPH", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "percent of patients experiencing a response in 3 out of 4 weeks of treatment", 
            "measure": "Treatment Success", 
            "safety_issue": "No", 
            "time_frame": "4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01687985"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "serum chemistry", 
            "safety_issue": "Yes", 
            "time_frame": "4 weeks"
        }, 
        "source": "Braintree Laboratories", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Braintree Laboratories", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}